Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?

American Journal of Gastroenterology

Volumn 95, Issue 4, 2000, Pages 914-920

  Fallone, Carlo A ^a   Barkun, Alan N ^a   Friedman, Gad ^a   Mayrand, Serge ^a   Loo, Vivian ^a   Beech, Robin ^b   Best B sc, Linda ^c   Joseph, Lawrence ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE ASSOCIATION; ERADICATION THERAPY; ESOPHAGITIS; ESOPHAGUS PRESSURE; FEMALE; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-ULCER AGENTS; BISMUTH; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DUODENAL ULCER; ESOPHAGITIS, PEPTIC; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; TREATMENT FAILURE;

EID: 0034072416     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00721-8     Document Type: Article

References (47)

1. Anonymous. The report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 1997;113(suppl):S4-S8.
2. Anonymous. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997;41:8-13.
3. Hunt R., Thomson A.B.R. Canadian Helicobacter pylori Consensus Conference. Can J Gastroenterol. 12:1998;31-41.
4. Talley N.J., Vakil N., Ballard E.D. II, Fennerty M.B. Absence of benefit of eradication of Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med. 341:1999;1106-1111.
5. McColl K., Murray L., El-Omar E., et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med. 339:1999;1869-1874.
6. Ofman J.J., Etchason J., Fullerton S., et al. Management strategies for Helicobacter pylori-seropositive patients with dyspepsia Clinical and economic consequences . Ann Intern Med. 126:1997;280-291.
7. Sonnerberg A. Cost-benefit analysis of testing for Helicobacter pylori in dyspeptic subjects. Am J Gastroenterol. 91:1996;1773-1777.
8. Makris N., Barkun A.N., Fallone C.A., et al. What is the most cost-effective strategy when managing young dyspeptic patients in the primary care setting? Gastroenterology. 116:1999;A120.
9. Labenz J., Blum A.L., Bayerdorffer E., et al. Curing Helicobacter pylori infection in patients with duodenal ulcer disease may provoke reflux esophagitis. Gastroenterology. 112:1997;1442-1447.
10. Vicari J.J., Peek R.M., Falk G.W., et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 115:1998;50-57.
11. Ödman B., Lindberg G., Befrits R., et al. Gastro-oesophageal reflux in duodenal ulcer patients after treatment for H. pylori during a two-year follow-up. Gut. 43:(suppl 2):1998;A99.
12. Vicari J.J., Peek R.M., Falk G.W., et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology. 115:1998;50-57.
13. Fallone C.A., Barkun A.N., Göttke M.U., et al. Helicobacter pylori cagA, cagE and vacA genotype associations with gastroesophageal reflux disease (GERD) and other upper gastrointestinal diseases. Gut. 45:(suppl 111):1999;A82.
14. Armstrong D., Bennett J.R., Blum A.L., et al. The endoscopic assessment of esophagitis A progress report on observer agreement . Gastroenterology. 111:1996;85-92.
15. Fallone CA, Barkun AN, Göttke MU, et al. Association of Helicobacter pylori genotype with gastroesophageal reflux disease and other upper gastrointestinal diseases. Am J Gastroenterol 2000;95:659-69.
16. Mullis K, Faloona F, Scharf S, et al. Specific enzymatic amplification of DNA in vitro: The polymerase chain reaction. Cold Spring Harbor Symposia on Quantitative Biology 1986;51:263-73.
17. Censini S., Lange C., Xiang Z., et al. Cag, a pathogenicity island of Helicobacter pylori, encodes type I-specific and disease-associated virulence factors. Proc Natl Acad Sci USA. 93:1996;14648-14653.
18. Atherton J.C., Cao P., Peek R.M. Jr, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori Association of specific vacA types with cytotoxin production and peptic ulceration . J Biol Chem. 270:1995;17771-17777.
19. Best L.M., Veldhuyzen van Zanten S.J., Bezanson G.S., et al. Serological detection of Helicobacter pylori by a flow microsphere immunofluorescence assay. J Clin Microbiol. 30:1992;2311-2317.
20. Best L.M., Veldhuyzen van Zanten S.J., Sherman P.M., et al. Serological detection of Helicobacter pylori antibodies in children and their parents. J Clin Microbiol. 32:1994;1193-1196.
21. Best L.M., Veldhuyzen van Zanten S.J. Detection of antibodies to H. pyloric cagA protein by flow cytometric immunoassay. Gut. 39:(suppl 2):1996;A120.
22. Peek R.M., Miller G.G., Tham K.T., et al. Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains. Lab Invest. 71:1995;760-770.
23. Feldman M., Cryer B., Lee E. Effects of Helicobacter pylori gastritis on gastric secretion in healthy human beings. Am J Physiol. 274:1998;G1011-G1017.
24. Jaup B. Gastroesophageal reflux after cure of H. pylori infection. Gastroenterology. 113:1997;2019.
25. El-Omar E., Oien K., Wirz A., et al. Divergent effects of H. pylori on acid secretion. Gastroenterology. 110:1996;A102.
26. El-Omar E., Oien K., Nujuni A.E., et al. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology. 113:1997;15-24.
27. Iijima K., Ohara S., Sekine H., et al. Increased acid secretion after Helicobacter pylori eradication is the important risk factor of acute duodenitis and reflux esophagitis. Nippon Rinsho. 57:1999;196-200.
28. Bercík P., Verdú E.F., Armstrong D., et al. H. pylori related increase in omeprazole (ome) effect is associated with ammonia production. Gastroenterology. 110:1996;A64.
29. Bercík P., Verdú E.F., Armstrong D., et al. Apparent increase in acid output during omeprazole after cure of H. pylori infection. Gastroenterology. 112:1997;A70.
30. Labenz J., Tillenburg B., Peitz U., et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology. 110:1996;725-732.
31. Verdu E.F., Armstrong D., Idstrom J.-P., et al. Effect of curing Helicobacter pylori infection on intragastric pH during omeprazole treatment. Gut. 37:1995;743-748.
32. Holtmann G., Cain C.R., Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology. 117:1999;11-16.
33. Talley N.J., Hunt R.H. What role does Helicobacter pylori play in dyspepsia and nonulcer dyspepsia? Arguments for and against H. pylori being associated with dyspeptic symptoms. Gastroenterology. 113:1997;S67-S77.
34. Pieramico O., Ditschuneit H., Malfertheiner P. Gastrointestinal motility in patients with non-ulcer dyspepsia A role of Helicobacter pylori infection? Am J Gastroenterol. 88:1983;364-368.
35. Minocha A., Mokshagundam S., Gallo S.H., et al. Alterations in upper gastrointestinal motility in Helicobacter pylori nonulcer dyspepsia. Am J Gastroenterol. 89:1994;1797-1800.
36. Caballero-Plasencia A.M., Muros-Navarro M.C., Martin-Ruiz J.L., et al. Dyspeptic symptoms and gastric emptying of solids in patients with functional dyspepsia Role of Helicobacter pylori infection . Scand J Gastroenterol. 30:1995;745-751.
37. Gilja O.H., Hausken T., Wilhemsen I., et al. Impaired accommodation of proximal stomach to a meal in functional dyspepsia. Dig Dis Sci. 41:1996;689-696.
38. Caldwell S.H., Valenzuela J.G., Marshall B.J., et al. Helicobacter pylori infection and gastric emptying of solids in humans. J Gastrointest Motil. 4:1992;113-117.
39. Mearin F., de Ribot X., Balboa A., et al. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut. 37:1995;47-51.
40. Jensen D.M., McCallum R., Walsh J.H. Failure of atropine to inhibit gastrin-17 stimulation of the lower esophageal sphicnter in man. Gastroenterology. 75:1978;825-827.
41. Werdmuller B.F., Loffeld R.J. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci. 42:1997;103-105.
42. Wu J.C., Sung J.J., Ng E.K., et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease A study from the East . Am J Gastroenterol. 94:1999;1790-1794.
43. Leodolter A., Dominguez-Munoz J.E., Gerards C., et al. Impact of Helicobacter pylori infection on gastroesophageal reflux. Gastroenterology. 114:1998;A200.
44. Marshall B.J. Epidemiology of H. pylori in western countries. Hunt R.H., Tytgat G.N.J. Helicobacter pylori. Basic mechanisms to clinical cure. 1994;75-84 Kluwer Academic Publishers, Dordrecht.
45. Hesketh P.J., Clapp R.W., Doos W.G., et al. The increasing frequency of adenocarcinoma of the esophagus. Cancer. 64:1989;526-530.
46. Labenz J., Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease Causal agent, independent or protective factor? Gut. 41:1997;279-280.
47. Graham D.Y. Helicobacter pylori infection in the pathogenesis of duodenal ulcer and gastric cancer A model . Gastroenterology. 113:1997;1983-1991.